Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 17th, 2026

LECO_Weekly-Healthcare-News_8-17-2026Download

Healthcare Weekly News and Deals

  1. Teledyne Technologies (NYSE: TDY) has entered a definitive agreement to acquire Varex Imaging Corporation (NASD: VREX) for $18.90 per share in cash, valuing the X-ray component maker at approximately $1.1 billion. Teledyne is paying roughly $1.1 billion in cash for Varex, extending a medical imaging build-out that began with the 2011 Teledyne DALSA purchase and the 2017 Teledyne e2v deal. Executive Chairman Robert Mehrabian framed the fit as complementary with minimal overlap: Teledyne lacks detectors for high-radiation oncology environments and photon-counting technology, both of which Varex supplies. Both boards approved unanimously; closing is targeted for early 2027 pending regulatory and Varex shareholder approval. Shareholder litigation is reportedly being weighed over whether the price adequately compensates Varex holders. (Link)
  2. Astorg has completed the carve-out acquisition of Thermo Fisher Scientific’s (NYSE: TMO) global microbiology business Astorg has closed a $1.075 billion carve-out of Thermo Fisher’s microbiology unit, structured as cash plus a $50 million seller note. The asset generated $645 million of 2025 revenue inside Thermo Fisher’s Specialty Diagnostics segment, serving over 15,000 customers across more than 100 countries with roughly 2,400 employees at 13 manufacturing and R&D sites. Judith Charpentier, Co-Managing Partner and Head of Healthcare at Astorg, positioned it as the complex-carve-out profile the firm targets. The business will run independently under CEO Dirk Bontridder and rebrand later in 2026. (Link)
  3. Affordable Care, LLC has completed a recapitalization transferring ownership to its existing lenders, cutting debt by approximately $1.0 billion and injecting $75 million of new capital. Affordable Care, the Morrisville, North Carolina dental support organisation, has closed a balance-sheet restructuring that hands ownership to its lender group. The transaction reduces debt by roughly 65%, or about $1.0 billion, provides $75 million of fresh capital and extends maturities to 2031. This is a creditor-led ownership change rather than a sponsor sale: the incoming lender owners are positioned as aligned with a longer-horizon plan. Deleveraging is intended to free capacity for reinvestment in supported practices, clinical capability, operating infrastructure and patient experience — a familiar reset for over-levered DSO platforms. (Link)
  4. PTC Therapeutics (NASD:PTCT) to acquire ST-920 Fabry disease gene therapy program for $111 million upfront plus milestones PTC Therapeutics has been selected as the winning bidder to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. Terms include $111 million upfront and up to $100 million in contingent regulatory milestones. A rolling BLA submission is expected to be completed in Q4 2026, with potential commercial launch in 2027. The deal leverages PTC’s existing rare disease commercial infrastructure. (Link)
  5. Fulcrum Therapeutics (NASD:FULC) and Slate Medicines announce merger agreement with concurrent $245 million private placement Fulcrum Therapeutics and privately held Slate Medicines have entered a definitive all-stock merger agreement. The combined company will operate as Slate Medicines and focus on next-generation migraine therapies, led by clinical-stage candidate SLTE-1009. Concurrently, Slate secured an oversubscribed $245 million private placement from a syndicate including Frazier Life Sciences, Forbion, RA Capital and others, expected to fund operations into 2029. Closing is targeted for the fourth quarter of 2026. (Link)
  6. EnableComp has acquired Helix Advisory, a Cincinnati, Ohio-based revenue recovery firm, to advance Zero Balance Review technology within its complex revenue recovery platform. EnableComp, the Franklin, Tennessee complex revenue cycle management provider, has acquired Ohio-based Helix Advisory. Terms were undisclosed and both parties are private. The acquisition closes a product gap: EnableComp already recovers roughly $3 billion annually across more than 1,000 hospitals in complex claims and denials, but lacked zero balance review — claims already paid, closed and filed, but paid incorrectly. Helix contributes underpayment detection beyond rules-based logic, clinical signal detection and root-cause analytics, folded into the e360 RCM platform. Founder Zack Higbie joins as VP of Revenue Recovery Products, citing early client net revenue improvements exceeding 2%. (Link)
  7. CHG Healthcare has acquired KREWE Anesthesia, a CRNA-founded staffing firm, to expand certified registered nurse anesthetist staffing and managed anesthesia services. CHG Healthcare, the Salt Lake City-area physician and advanced-practice workforce company, has acquired KREWE Anesthesia. Terms were undisclosed and both parties are private. The investment case rests on scarcity: CHG’s own research ranks CRNAs among the hardest advanced-practice roles to fill nationally, with rural hospitals especially dependent on CRNA-led anesthesia to sustain surgical volume. Founded in 2022, KREWE reports roughly 84% annual clinician retention, materially above locum tenens benchmarks. CEO Leslie Snavely framed the deal as capability plus cultural fit. Founders Gavin Baker and Chase Chiasson remain as CEO and President. (Link)
  8. Viome Life Sciences has acquired Circulate Health, the therapeutic plasma exchange provider, adding clinical delivery to its molecular diagnostics and precision nutrition platform. Viome Life Sciences, the Bellevue, Washington preventive health company founded in 2016, has acquired Circulate Health. Financial terms were not disclosed and both are private. The acquisition converts Viome from a diagnostics-and-recommendations business into one owning the intervention layer, expanding the combined platform to more than 200 partner clinics. Circulate contributes physician-guided therapeutic plasma exchange delivered outside hospital settings, with published research associating its protocol with an average 2.6-year biological age reduction and measurable microplastic reduction. Founder Naveen Jain framed the thesis around measurable, repeatable health improvement. Circulate CEO Brad Younggren becomes president of Viome PRO. (Link)
  9. Kyndryl (NYSE: KD) has agreed to acquire Healthcare IT Leaders, LLC, an enterprise IT services provider to hospitals and health systems, to accelerate AI-led modernization for providers and payors. Kyndryl is buying Healthcare IT Leaders to bolt a consulting and application managed services layer onto its existing infrastructure position in U.S. healthcare. Terms were undisclosed. Jamie Rutledge, president of Kyndryl U.S., framed demand as coming from providers under pressure across clinical, operational and workforce systems while maintaining resiliency and compliance. Strategically, this moves Kyndryl up the stack: it already runs large regulated IT environments, and the target deepens relationships with national health systems across federal, academic, pediatric and regional segments. Closing is expected in Kyndryl’s fiscal 2027 second quarter. (Link)
  10. DermCare Management, LLC and U.S. Dermatology Partners have completed a strategic combination creating one of the largest dermatology group practices in the United States, spanning 12 states. DermCare Management and U.S. Dermatology Partners have closed a combination uniting two physician-led platforms across 12 states. Financial terms were not disclosed and both are privately held. The combined organisation will serve more than three million patients annually — DermCare contributes over 270 providers and more than one million patients across Florida, Texas, Virginia, North Carolina and California, while USDP treats over two million patients across nine states. Scale economics drive the rationale: national clinical trial infrastructure, expanded provider education and shared practice technology. DermCare founder Jeffrey Schillinger becomes Executive Chair; USDP’s Paul Singh leads as President and CEO. (Link)
  11. LLR Partners and LNK Partners-backed Schweiger Dermatology Group has acquired Saratoga Dermatology, expanding its footprint across the greater Albany, New York market. Schweiger Dermatology Group, backed by private equity sponsors LLR Partners and LNK Partners, acquired Saratoga Dermatology on August 5, 2026. Financial terms of the private transaction were not disclosed. The target operates outpatient clinics in Saratoga Springs and Clifton Park under Drs. Jean Buhac, Christopher Heath and John Buhac, delivering medical, surgical and cosmetic dermatology. The sponsors’ model is density plus centralisation: SDG already runs more than 65 offices and roughly 200 providers across the Northeast, and the addition concentrates upstate New York coverage while folding the practice into shared operational infrastructure. (Link)
  12. Little Rock, Arkansas-based Rock Dental Brands has partnered with TLC Pediatric Dentistry & Orthodontics, a Tampa, Florida specialty practice led by Dwight Sanjuan, DMD, and Robertzon Guloy, DMD. Rock Dental Brands has added TLC Pediatric Dentistry & Orthodontics in Tampa, extending its multi-specialty DSO platform into the Florida market. Deal terms were not disclosed and both parties are private. Launched in 2003, TLC pairs pediatric dentistry with orthodontics under two clinician owners, a dual-specialty configuration consolidators favour because it captures a patient across a longer treatment arc and internalises referral flow. Dr. Sanjuan holds memberships in the American Academy of Pediatric Dentistry, the Florida Academy of Pediatric Dentistry and the International Association of Pediatric Dentistry. The transaction reflects continued single-practice tuck-in activity in dental support organisations. (Link)
  13. DuneGlass Capital-backed Phase 1 Equity has acquired a multi-site orthodontic practice in North Dakota, marking its fourth practice addition of 2026 and its 23rd doctor. Phase 1 Equity, the Chicago-headquartered doctor-owned platform launched by DuneGlass Capital in 2022, has added a multi-site North Dakota orthodontic practice. Terms were undisclosed. The transaction is Phase 1’s fourth addition of 2026, its first in North Dakota, and lifts the platform to 23 doctors across 33 locations nationally. The differentiator is the sponsor’s proprietary Doctor Equity model, under which participating orthodontists and pediatric dentists retain full clinical and practice-level decision rights while accessing private-equity economics and network scale. DuneGlass Managing Partner Ryan Graham co-founded the platform as an alternative to conventional dental consolidation. (Link)
  14. WindRose Health Investors, LLC has completed the recapitalization of Verified Clinical Trials, LLC, the clinical trial subject registry provider, and appointed Howard Miller as Chief Executive Officer. WindRose Health Investors, the New York healthcare private equity firm managing roughly $8 billion, has recapitalized Verified Clinical Trials. Terms were undisclosed. Partner CJ Burnes described VCT’s platform as proactively reducing downstream risk across the clinical research chain. The underwriting logic is infrastructure rather than therapeutics: VCT’s secure global database detects duplicate enrolment and protocol violations at screening, and sixteen years of proprietary data assets create a defensible position. Capital funds data and analytics expansion for sponsors, CROs and trial sites. Founders Mitchell Efros, MD and Kerri Weingard, ANP remain actively involved post-close. (Link)
  15. Integrity, LLC has partnered with Meraz Health Insurance Agency, the Temecula, California Medicare-focused independent marketing organization led by Manuel “Manny” Meraz. Integrity, the Dallas-headquartered distributor of life and health insurance and provider of wealth and retirement solutions, has added Meraz Health Insurance Agency to its partner network. Financial details were not disclosed and both parties are private. The transaction follows Integrity’s established roll-up pattern in independent marketing organizations, where acquired agencies gain access to the IntegrityCONNECT AI platform, Ask Integrity voice assistant, marketing infrastructure and carrier breadth. Meraz brings a decade-long Medicare Advantage, prescription drug and Medicare supplement book with deep Latino community distribution — a demographic channel with structural growth in Medicare enrolment. (Link)
  16. Denver-based Mountaingate Capital has fully exited its investment in Relevate Health, the Cincinnati, Ohio-based healthcare commercialization platform, after a six-year partnership. Mountaingate Capital, a lower-middle-market firm partnering with founders and entrepreneurs, has exited Ohio-based Relevate Health, closing August 5, 2026. Terms were undisclosed and the buyer was not identified. Mountaingate first invested in 2020, and the value-creation plan ran through four add-on acquisitions plus investment in Relevate’s proprietary ELE Decision Engine, product suite, infrastructure and leadership team. Co-Founder and Managing Director Bruce Rogers framed the outcome as validation of the original thesis. The firm characterises it as another strong result in tech-enabled, analytics-driven marketing services — a sector where Mountaingate has now realised repeat exits. (Link)
  17. Global systems integrator Myriad360 has acquired the assets of healthcare-focused F3 Technology Partners, pushing the combined platform past the $1 billion annual revenue. Myriad360, the West Deptford, New Jersey-based systems integrator, has purchased the assets of F3 Technology Partners, a West Hartford, Connecticut provider with a longstanding healthcare and financial services vertical. Terms were not disclosed and both are private. The deal follows Myriad360’s February 2026 acquisition of Ohio-based AdvizeX Technologies, which alone created a roughly $900 million run-rate platform; F3 carries the combined business across $1 billion. The strategic driver is channel consolidation — vendor programmes increasingly favour scaled partners, and healthcare vertical depth commands premium positioning in a fragmented integrator market. (Link)
  18. Gridiron Capital, LLC has partnered with van den Boom & Associates, the San Diego-based outsourced back-office services provider to emerging life sciences companies, under founder Esther van den Boom’s continued leadership. Gridiron Capital, the New Canaan, Connecticut firm focused on founders, entrepreneurs and management teams, has invested in van den Boom & Associates. Financial terms were not disclosed. The deal advances Gridiron’s Outsourced Pharma Services Thematic Area of Expertise and builds on prior healthcare and pharma-adjacent services investments. Principal Aaron Stoppelmann framed the thesis around two converging trends: growth in venture-backed life sciences companies and their preference for specialised operational partners. vdB&A serves 160-plus active clients with 150-plus professionals across finance, HR, contract management, compliance and a newly launched IT managed services line. (Link)
  19. Marlin Equity Partners-backed Radar Healthcare has acquired patient experience and patient-reported outcomes platform Cemplicity, following its earlier purchase of EIDO Healthcare. Radar Healthcare, the quality, risk and compliance software provider backed by Marlin Equity Partners, has acquired Cemplicity. Terms were undisclosed and both parties are private. The sponsor thesis is adjacency stacking rather than scale: Cemplicity contributes patient experience measurement, patient-reported outcomes and real-time patient insight, which Radar pairs with its existing quality, risk and improvement workflows. Chief Executive Edward Bellamy positioned the logic as connecting what patients report to the workflows needed to act on it. The deal follows Radar’s acquisition of digital consent provider EIDO Healthcare, extending a buy-and-build across the quality-and-safety software stack. (Link)
  20. The Riverside Company adds Yellow Emperor to Western Botanicals The Riverside Company has made Yellow Emperor its first add-on investment for portfolio company Western Botanicals. The Eugene, Oregon-based CDMO specializes in custom liquid dietary supplement formulations, providing end-to-end services from ingredient sourcing through manufacturing, bottling and packaging. The combination deepens Western Botanicals’ liquid capabilities and strengthens its position as a formulator and manufacturing partner for health and wellness brands. (Link)
  21. Sarnova, Patricia Industries portfolio company, acquires Mercury Medical Sarnova, a national specialty distributor of emergency medical services and acute care products, has acquired Mercury Medical. The Clearwater, Florida-based company designs, manufactures and distributes critical care and emergency medical devices. The deal expands Sarnova’s product portfolio across its Bound Tree Medical, Cardio Partners, Emergency Medical Products and Tri-anim Health Services units. (Link)
  22. Livingbridge has put teleradiology group Everlight Radiology up for sale at around $1 billion, with Radiology Partners reported to be the front-runner UK mid-market firm Livingbridge is running a roughly $1 billion sale of Everlight Radiology. The process is now in its late stages, with Radiology Partners reported to be leading. An Everlight exit would hand Livingbridge a large realisation from a cross-border teleradiology asset, while a Radiology Partners win would extend the US-based radiology platform’s reach into Australian and UK night-hawking volumes. Radiology reading remains one of the most actively consolidated healthcare services niches for private capital. (Link)
  23. Curium acquires Abscint, expanding its PET radiodiagnostic pipeline in oncology Curium, a global radiopharmaceutical company, has completed the acquisition of Abscint SA, a Belgian clinical-stage company developing PET imaging agents for oncology. The deal adds ABS-011, an investigational gallium-68-labeled PET tracer targeting HER2 that is currently in a Phase 2b trial. Curium gains global rights to develop, manufacture and commercialize the asset, strengthening its radiodiagnostic capabilities in breast and gastric cancers. (Link)

Venture Deals and Other

  1. Soleus Capital has led a $110 million Series C and debt financing in Bridge to Life Ltd., with Lauxera Capital Partners participating and Soleus Capital Credit Opportunities Fund providing the debt tranche. Soleus Capital, the Greenwich firm with roughly $3.5 billion in assets under management, led the equity alongside Lauxera Capital Partners, which manages over $1 billion across 14 healthtech portfolio companies; Bridge to Life directors, officers and employees also participated. Partner Ben Lund cited the pairing of an established preservation franchise with a newly FDA-cleared perfusion platform. Proceeds refinance the Perceptive Credit Funds facility — cutting leverage and interest cost — and fund the VitaSmart HOPE System commercial build-out to every U.S. transplant center, plus a viability assessment tool and multi-organ pipeline. (Link)
  2. Bessemer Venture Partners has led a $50 million Series B in Flagler Health, with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Venture Partners and Offscript. Bessemer Venture Partners led the $50 million Series B for New York-based Flagler Health, taking total funding to $63 million. Partner Steve Kraus pointed to the founding team’s combination of healthcare operations experience, clinical authority and AI expertise applied to a large underserved market. Investors are backing demonstrated unit economics rather than promise: in under three years Flagler has scaled to thousands of providers across more than 36 states, delivering an average $164,000 in additional annual revenue per provider, with 87% of patients reporting improvement. Musculoskeletal care represents over $400 B in annual U.S. spend. (Link)
  3. OG Venture Partners and M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany (ETR: MRK), have co-led a $36 million Series A in Remepy, joined by NFX, Qumra Capital, Tadmor Group, TechAviv and Vine Ventures. OG Venture Partners and M Ventures, the strategic venture arm of Merck KGaA (ETR: MRK), led Remepy’s $36 million Series A, lifting total capital raised to $62 million. The strategic investor’s participation is notable given Merck KGaA’s existing hybrid drug development partnership with Remepy covering multiple indications, starting with rare tumours. Proceeds fund a global Phase III trial of lead asset Hybridopa in Parkinson’s disease, commencing in the fourth quarter of 2026, following positive Phase IIa motor and non-motor data. Investors are betting on evolving U.S. regulatory frameworks for drug-software combination products. (Link)
  4. Redmile Group, Vsquared Ventures and Kindred Capital have co-led a $25 million seed round in Bios Life, which signed a multi-year data alliance with Tempus AI (NASD: TEM). Redmile, Vsquared Ventures and Kindred Capital led the $25 million seed for Bios Life, joined by healthcare and technology investors across the United States and Europe — an unusually deep syndicate for a company emerging from stealth. Investors are underwriting a founder-pedigree and data-moat thesis: CEO Ryan Richardson was BioNTech’s chief strategy officer and chaired InstaDeep, and the company holds commercial rights to the Nucleotide Transformer genomics foundation model. The Tempus alliance supplies de-identified multi-modal oncology data for training, with Tempus-owned Ambry Genetics adding hereditary testing. Launch is slated for second-half 2026. (Link)
  5. Battery Ventures has made a significant growth investment in Vetspire, the AI operating system for veterinary practices, carving it out as a standalone company from Thrive Pet Healthcare. Battery Ventures, a global technology-focused investment firm founded in 1983, is backing Vetspire as an independent business, with Thrive Pet Healthcare retaining no ownership going forward while remaining a long-term customer. Terms were undisclosed. General Partner Chelsea Stoner cited timing: Covid-era adopted pets are aging into higher care needs. Battery brings a track record in specialty-healthcare EHR and practice-management platforms including Brightree, ClearCare, ContinuumCloud, Curve Dental and WebPT. Vetspire runs at more than 800 hospitals and clinics; Zachary Seely joins as CEO. (Link)
  6. XiFin, Inc. has made a strategic investment in Denver-based Notable Systems as part of Notable’s Series B financing, alongside a multi-year agentic AI alliance across revenue cycle management. XiFin has invested in Notable Systems’ Series B while committing to a multi-year technology alliance. The investment amount was not disclosed and both companies are private. Executive Chair and CEO Lâle White framed the capital commitment as reinforcing XiFin’s position in intelligent revenue cycle management. Notable’s document intelligence will be embedded into the XiFin Empower AI RCM ecosystem, targeting requisitions, prescriptions, medical records and payer correspondence. Notable serves enterprise DME providers including Orthofix (NASD: OFIX) and National Seating & Mobility. (Link)

CLICK HERE to sign up
for all news and updates